8-K: Salarius Pharmaceuticals Gains Nasdaq Extension

Salarius Pharmaceuticals, Inc. received an extension from Nasdaq to regain compliance with its Equity Standard by October 20, 2025, following a recent reverse stock split.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) received an additional extension from The Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5550(b)(1) (the Equity Standard) until October 20, 2025.
• The company expects to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement) by August 29, 2025, after implementing a 1-for-15 reverse stock split on August 15, 2025.
• Salarius had previously received a delisting notice on April 23, 2025, for failing the Minimum Bid Price Requirement and a letter on March 26, 2025, for non-compliance with the Equity Standard based on its 2024 Form 10-K.
• The company appealed Nasdaq's determination, which led to a hearing process and subsequent extensions to address these compliance issues.

Sentiment

Score: 4

Explanation: The company secured an extension and took action on the bid price, averting immediate delisting. However, it remains in a precarious position regarding Nasdaq compliance, indicating underlying operational or financial challenges that led to non-compliance in the first place. The repeated extensions suggest ongoing difficulty in meeting requirements.

Positives

• Granted an additional extension by the Nasdaq Hearings Panel to regain compliance with the Equity Standard until October 20, 2025, thereby avoiding immediate delisting.
• Successfully effected a 1-for-15 reverse stock split on August 15, 2025, and expects to regain compliance with the Minimum Bid Price Requirement by August 29, 2025.

Negatives

• The company remains non-compliant with Nasdaq's Equity Standard and Minimum Bid Price Requirement, necessitating multiple extensions and a reverse stock split.
• Was not eligible for the standard 180-calendar day compliance period for the Minimum Bid Price Requirement due to a prior reverse stock split within the last year.
• Failure to comply with the Minimum Bid Price Requirement served as an additional reason for delisting, initially preventing Nasdaq from entertaining a Compliance Plan for the Equity Standard.

Risks

• Failure to regain compliance with the Nasdaq Equity Standard by October 20, 2025, could lead to delisting.
• Failure to maintain compliance with the Nasdaq Minimum Bid Price Requirement after the reverse stock split could lead to further delisting actions.
• General market conditions and other risks detailed in the company's Securities and Exchange Commission filings, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Future Outlook

Salarius Pharmaceuticals expects to regain compliance with the Nasdaq Minimum Bid Price Requirement by August 29, 2025, following its recent reverse stock split. The company also aims to regain compliance with the Nasdaq Equity Standard by October 20, 2025, as per the latest extension granted by the Nasdaq Hearings Panel.

Management Comments

• Salarius expects to regain compliance with the Minimum Bid Price Requirement by Nasdaq's deadline of August 29, 2025.

Industry Context

This filing highlights the ongoing challenges faced by smaller biotechnology and pharmaceutical companies in maintaining Nasdaq listing requirements, particularly regarding minimum bid price and equity standards. Such compliance issues can impact investor confidence and access to capital, a common hurdle for development-stage companies with limited revenue streams.

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of shares outstanding, potentially increasing the per-share price but not the overall market capitalization. Continued non-compliance or delisting would negatively impact liquidity and investor confidence. The extension provides temporary relief from delisting.
• Employees: No direct impact mentioned, but delisting could create uncertainty regarding the company's future.
• Creditors: No direct impact mentioned, but delisting could affect the company's ability to raise capital, potentially impacting future financial stability.

Next Steps

• Regain compliance with the Nasdaq Minimum Bid Price Requirement by August 29, 2025.
• Regain compliance with the Nasdaq Equity Standard by October 20, 2025.
• Notify Nasdaq of achievements regarding scheduled milestones.

Key Dates

Recommendation

While Salarius Pharmaceuticals has successfully secured an extension to remain listed on Nasdaq and taken steps to address the minimum bid price, the underlying issues leading to non-compliance with both the Equity Standard and Minimum Bid Price Requirement persist. The repeated need for extensions and a reverse stock split indicates ongoing operational or financial challenges. Investors should hold to see if the company can definitively regain and maintain compliance by the new deadlines and address the fundamental issues, but significant upside is unlikely until more stable financial performance is demonstrated.

Keywords

Salarius Pharmaceuticals, SLRX, Nasdaq, Delisting, Equity Standard, Minimum Bid Price, Reverse Stock Split, Compliance Extension, Biotechnology, Pharmaceuticals